Cancer

Bristol-Myers Squibb Funds Cancer Treatment Collaboration Grants

The company has donated a total of $175,000 to the American Cancer Society and Princeton HealthCare System to support cancer treatment and patient care.

Bristol-Myers Squibb has awarded grants totaling $175,000 to the American Cancer Society Eastern Division and Princeton HealthCare System (PHCS) to support comprehensive navigation services for patients with cancer both independently and as part of a collaborative effort among several hospitals in central New Jersey.

Your rating: None Average: 5 (1 vote)

Cylene Pharmaceuticals Calls on TetraGene to Advance Anti-Cancer Technologies

The agreement is aimed to advance the ocmpany’s quadruplex-targeting technologies.

Cylene Pharmaceuticals, Inc. announced today that it has entered into an exclusive, worldwide Option and License Agreement that will allow TetraGene LLC to advance the development of Quarfloxin and Cylene's associated anticancer quadruplex-targeting technologies. Cylene will receive an upfront fee, as well as potential milestone payments and royalties on product sales for the exclusive license. 

No votes yet

Araxes Pharma, Janssen Biotech to Partner on Cancer Drug Development

The pharmaceutical packaging and product firm is looking to develop oncological therapeutics through the partnership.

Araxes Pharma LLC announced today it has entered into an exclusive arrangement with Janssen Biotech, Inc. to develop first-in-class therapeutics against a certain target for the treatment of cancer.

No votes yet

Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from FDA

The company attained the designation for ibrutinib monotherapy for parients with two different B-cell malignancies.

Pharmacyclics, Inc. announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to the investigational oral agent ibrutinib monotherapy for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL) and to ibrutinib monotherapy for the treatment of patients with Waldenstrom’s macroglobulinemia (WM), both of which are B-cell malignancies.

No votes yet

New York Pharmaceutical Distributor Caught with Counterfeit Avastin

The FDA is warning physicians to be on the lookout for fake versions of Roche’s cancer drug.

The Food and Drug Administration is warning doctors about another counterfeit version of the cancer drug Avastin distributed in the U.S., the third case involving the best-selling Roche drug in the past year.

No votes yet

New York Pharmaceutical Distributor Caught with Counterfeit Avastin

The FDA is warning physicians to be on the look out for fake versions of Roche’s cancer drug.

The Food and Drug Administration is warning doctors about another counterfeit version of the cancer drug Avastin distributed in the U.S., the third case involving the best-selling Roche drug in the past year.

No votes yet

ScinoPharm, Foresee Pharmaceuticals to Partner on Oncological Drug Development

The companies will work together to develop new oncological peptide drugs.

ScinoPharm and Foresee Pharmaceuticals, Inc. (Foresee) jointly announced today that an investment agreement to form a joint venture has been signed. This venture looks to develop a series of peptide injectable drugs with the first being a new oncological Leuprolide injectable drug product, where Leuprolide will be formulated in a proprietary controlled-release drug delivery system originally developed by Foresee and transferred to the joint venture. ScinoPharm commits to invest USD3.6 million for a minority ownership in the new company.

No votes yet

GVK Biosciences, Onconova Therapeutics to Partner on Cancer Drug Development

The pharmaceutical companies have formed a joint development partnership to advance new drugs for oncology patients.

GVK BIO, Asia’s leading Contract Research and Development organization and Onconova Therapeutics, a U.S. based biopharmaceutical company primarily focused on discovery and development of novel small molecules for Oncology, today announced that they have entered into a novel joint partnership to develop new drugs for Cancer.

No votes yet

Geron to Halt Brain-cancer Drug Development

The pharma firm reports it will trim its brain-cancer development efforts and staff to focus on other research.

Geron Corp. said it has stopped developing its treatment for brain cancers, and will cut its work force and replace its chief financial officer.

The pharmaceutical company said it plans to reduce its work force by 40% to 64 full-time positions. It expects to lower its annual cash operating expenses from about $65 million in 2012 to about $33 million in 2013--which includes nonrecurring costs of about $3 million associated with the restructuring and about $3 million for the discontinuation of clinical trials.

No votes yet

GTx to Present Testosterone Treatment for Prostate Cancer Patients

Capesaris is indicated to reduce free testosterone in men with castration-resistant prostate cancer.

 GTx Inc. announced today there will be a presentation on the mechanism of action of Capesaris® to induce sex hormone binding globulin (SHBG) and subsequently reduce free testosterone (FT) in men with castration resistant prostate cancer.

No votes yet
Syndicate content